Navigation Links
Martek to Announce Second Quarter 2009 Results
Date:5/20/2009

COLUMBIA, Md., May 20 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its second quarter of fiscal 2009 on June 3, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.

An archived webcast of the conference call will be available on the Martek's website for thirty days. In addition, a recorded playback of the call will be available for one week and can be accessed by calling 800-633-8284 or 402-977-9140 and entering pass code 214 25 390.

Martek Biosciences Corporation is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The Company produces life'sDHA, a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula and supplements, and life'sARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com/.

    Contact:
    Kyle Stults
    Investor Relations
    (410) 740-0081

    Cassie France-Kelly
    Public Relations
    (410) 740-0081


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
10. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... -- Ambit Biosciences Corporation announced today the enrollment and ... Cancer Center of the first patient in the ACE ... fficacy) Phase 2 pivotal trial in patients with ... is a novel, orally available, potent and highly selective ... tyrosine kinase-3 (FLT3) inhibitor. The ACE study is ...
(Date:12/11/2009)... - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ... of Dr. Alan Warrander to the role of ... ,, "Dr. Warrander will be responsible for the ... said Dr. Brad Thompson, President and CEO of ... of a Phase 3 trial examining REOLYSIN in ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
Breaking Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2
... Jan. 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ... JPMorgan Healthcare Conference on Monday, January 7, at ... live webcast of the,presentation at:, http://www.metameetings.com/webcasts/jpmorgan/healthcare08 ... on 15 minutes early in order to,register and ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it ... U.S. Food and Drug Administration (FDA) requesting approval ... of patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who ... a rituximab-containing,regimen. According to the National Cancer Institute, ...
... Dec. 28 Beckman Coulter,Inc. (NYSE: ... marketer of,products that simplify, automate, and innovate ... Beckman Coulter,s president and chief,executive officer, will ... January 8, 2008, at 6:00 p.m. (ET)., ...
Other Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4
(Date:12/13/2009)... LA JOLLA, CADecember 10, 2009Researchers at The Scripps ... how a single protein from an ancient family ... in the body. In addition to providing guidance ... research supplies a theoretical underpinning for the protein,s ... macular degeneration. , The research was published in ...
(Date:12/11/2009)... green plants photosynthesize, absorb carbon dioxide and produce ... that photosynthesis has had on Earth. One of ... evolution of photosynthesis is Jeffrey Touchman, assistant professor ... , Oxygen, one of the by-products of photosynthesis ... (including algae and higher plants), transformed the Precambrian ...
(Date:12/11/2009)... professor of anthropology at the University of Arizona, has ... understand how violence shapes the health of those eking ... and her colleagues, research," Documenting the health consequences of ... A conceptual framework," is currently published in a special ... collaboration with the British medical journal the Lancet ...
Breaking Biology News(10 mins):Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3'Extreme' genes shed light on origins of photosynthesis 2'Extreme' genes shed light on origins of photosynthesis 3UA-led study grapples with health effects of low-intensity warfare 2Changing Paradigms in Hereditary Angioedema 3A Pathophysiology Diagnosis and Treatment 50301 1Changing Paradigms in Hereditary Angioedema 3A Pathophysiology Diagnosis and Treatment 50301 2Alpharmas Reach Teach Learn Initiative Targets Youth and Consumer Awareness 50298 1Alpharmas Reach Teach Learn Initiative Targets Youth and Consumer Awareness 50298 2Risk of cancer 50297 1
... University Hospital of Magdeburg (Germany) have discovered that ... oxidative stress followed by the activation of the ... gene expression in atrial tissue. Their study will ... Biology and Medicine. Multiple tachycardia-associated factors appear to ...
... of Chicago scientists has shown how two proteins locate ... protein detects and repairs damage in malignant cells that ... In a paper published in the April 24 issue ... of designing a molecule that could interfere with the ...
... available in German . , , Professor Wolfgang ... a physicist from Warsaw, have been selected to receive ... Research Foundation) and the Foundation for Polish Science (FNP) ... is in recognition of their many years of fruitful ...
Other Biology News:Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia 2Researchers reveal structure of protein that repairs damage to cancer cells 2Researchers reveal structure of protein that repairs damage to cancer cells 3Outstanding German-Polish scientific cooperation 2Outstanding German-Polish scientific cooperation 3
... PRO S-7 stirrers deliver accurate ... channels fluids away from internal ... easy-to-use controls which allow users ... ceramic tops feature a chemical ...
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... PYREX trypsinizing flasks are used ... into cell suspensions by digestion ... neck accepts cotton plugs. Four ... • Height of Baffles mm ...
... purified RNA samples for RT-PCR and microarray analysis. ... advantages and applications you expect from our StabMRT ... used for enzymatic applications such as RT-PCR and ... the stabilization of aqueous RNA samples that have ...
Biology Products: